Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Front Endocrinol (Lausanne). 2022 Feb 24;13:762589. doi: 10.3389/fendo.2022.762589. eCollection 2022.
Clear cell adenocarcinoma (CCA) is considered a relatively rare tumor with a glycogen-rich phenotype. The prognosis of CCA patients is unclear. In this study, recent trends in the epidemiological and prognostic factors of CCA were comprehensively investigated.
Patients with CCA from years 2000 to 2016 were identified from the Surveillance, Epidemiological, and End Results (SEER) database. Relevant population data were used to analyze the rates age-adjusted incidence, age-standardized 3-year and 5-year relative survivals, and overall survival (OS).
The age-adjusted incidence of CCA increased 2.7-fold from the year 2000 (3.3/100,000) to 2016 (8.8/100,000). This increase occurred across all ages, races, stages, and grades. Of all these subgroups, the increase was largest in the grade IV group. The age-standardized 3-year and 5-year relative survivals increased during this study period, rising by 9.1% and 9.5% from 2000 to 2011, respectively. Among all the stages and grades, the relative survival increase was greatest in the grade IV group. According to multivariate analysis of all CCA patients, predictors of OS were: age, gender, year of diagnosis, marital status, race, grade, stage, and primary tumor site ( < 0.001). The OS of all CCA patients during the period 2008 to 2016 was significantly higher than that from 2000 to 2007 ( < 0.001).
The incidence of CCA and survival of these patients improved over time. In particular, the highest increases were reported for grade IV CCA, which may be due to an earlier diagnosis and improved treatment.
透明细胞腺癌(CCA)被认为是一种相对罕见的肿瘤,具有丰富糖原的表型。CCA 患者的预后尚不清楚。本研究综合调查了 CCA 的流行病学和预后因素的最新趋势。
从监测、流行病学和最终结果(SEER)数据库中确定了 2000 年至 2016 年期间的 CCA 患者。使用相关的人口数据来分析年龄调整发病率、年龄标准化 3 年和 5 年相对生存率以及总生存率(OS)。
CCA 的年龄调整发病率从 2000 年的 3.3/100,000 增加到 2016 年的 8.8/100,000,增加了 2.7 倍。这种增加发生在所有年龄段、种族、分期和分级中。在所有这些亚组中,IV 级组的增加最大。在研究期间,年龄标准化的 3 年和 5 年相对生存率有所提高,分别从 2000 年到 2011 年提高了 9.1%和 9.5%。在所有分期和分级中,IV 级组的相对生存率提高最大。根据所有 CCA 患者的多变量分析,OS 的预测因素是:年龄、性别、诊断年份、婚姻状况、种族、分级、分期和原发肿瘤部位(<0.001)。2008 年至 2016 年期间所有 CCA 患者的 OS 明显高于 2000 年至 2007 年(<0.001)。
CCA 的发病率和患者的生存率随时间推移而提高。特别是 IV 级 CCA 的增加幅度最大,这可能是由于更早的诊断和改善的治疗。